New pill aims to halt lung scarring in thousands
NCT ID NCT07540988
First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 10 times
Summary
This study tests a drug called nerandomilast in 466 adults with fibrosing interstitial lung disease (ILD) who are at risk of worsening. Participants take either the drug or a placebo for at least 52 weeks. Doctors measure lung function and use CT scans to see if the drug slows disease progression.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- nerandomilast
- What this could lead to
- If it works, this could provide a new treatment option to slow lung function decline in people with fibrosing interstitial lung disease.
- What could go wrong
- This is a Phase 3 trial, but results are not yet available. The drug may not prove better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 466 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria : 1. Male and female individuals ≥18 years of age at the time of first signed informed consent at Visit 1a 2. Signed and dated written informed consent in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) and local legislation prior to admission to the trial 3. Diagnosis of fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) as established by the investigator 4. Presence of fibrotic lung disease on high resolution computed tomography (HRCT), defined as reticulation with traction bronchiectasis/ bronchiolectasis and/or honeycombing, and extent of fibrosis ≥10%, as assessed by central review prior to randomization 5. Time since ILD diagnosis ≤3 years before randomization 6. FVC ≥45% of predicted normal at Visit 1 7. Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥25% of predicted normal corrected for hemoglobin (Hb) at Visit 1 8. Patients treated with permitted immunosuppressive/immunomodulatory agents for an underlying systemic disease (e.g. methotrexate (MTX), azathioprine (AZA)) need to be on stable treatment for at least 12 weeks prior to Visit 1 and during screening period 9. Further inclusion criteria apply. Exclusion criteria : 1. Known diagnosis of idiopathic pulmonary fibrosis (IPF) based on multidisciplinary discussion (MDD) and according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2022 guidelines 2. Known diagnosis of autoimmune-ILDs other than rheumatoid arthritis-associated ILD (RA-ILD) 3. Known diagnosis of sarcoidosis 4. Patients with predominant features of organizing pneumonia on HRCT, as assessed by central review 5. Patients who developed ILD due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection/Coronavirus Disease 2019 (COVID-19) (based on investigators judgement) 6. Meeting criteria for progressive pulmonary fibrosis (PPF), as assessed by investigator 7. Meeting criteria for treatment with currently approved therapies for the fibrosing ILD (e.g. PPF), as assessed by investigator 8. Prior or current use of nerandomilast, nintedanib, or pirfenidone 9. Further exclusion criteria apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fibrosing interstitial lung disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
163 sites in 19 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
A.O. San Gerardo di Monza
Monza, 20900, Italy
-
AZ Delta
Roeselare, 8800, Belgium
-
Advanced Pulmonary Research Institute
Loxahatchee Groves, Florida, 33470, United States
-
Asan Medical Center
Seoul, 05505, South Korea
-
Avanza Medical Research Center
Pensacola, Florida, 32503, United States
-
Azienda Ospedaliera Universitaria di Padova
Padova, 35128, Italy
-
Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
Catania, 95124, Italy
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
-
Beijing Chao-Yang Hospital
Beijing, 100020, China
-
CIC Mauricie (Trois Rivieres)
Trois-Rivières, Quebec, G8T 7A1, Canada
-
CLARE - Clinica de Pneumologia
Goiânia, 74110-030, Brazil
-
Centre Hospitalier Universitaire de Liège
Liège, 4000, Belgium
-
Centro de Investigacion Farmacologica del Bajío, S.C.
León, 37160, Mexico
-
Centro de Investigacion Integral MEDIVEST S.C
Chihuahua City, 31203, Mexico
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
China Medical University Hospital
Taichung, 404, Taiwan
-
Churchill Hospital
Oxford, OX3 7LE, United Kingdom
-
Cleveland Clinic Florida
Weston, Florida, 33331, United States
-
Clinical Research Specialists LLC - Kissimmee
Kissimmee, Florida, 34746, United States
-
Clinical Trials Center of Middle Tennessee, LLC
Franklin, Tennessee, 37067, United States
-
Coastal Carolina Health Care, P.A. Pulmonary and Sleep Medicine
New Bern, North Carolina, 28562, United States
-
Coastal Pulmonary & Critical Care
St. Petersburg, Florida, 33704, United States
-
Columbia University Medical Center-New York Presbyterian Hospital
New York, New York, 10032, United States
-
Consultorios Medicos del Buen Ayre
Capital Federal, 1425, Argentina
-
Erasmus Medisch Centrum
Rotterdam, 3015 GD, Netherlands
-
Essence MD Research
Naples, Florida, 34102, United States
-
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, 510000, China
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, 00168, Italy
-
Fundacion Innovaciencia
Rosario, 2000, Argentina
-
Fundacion NIBA Neurologia Infantil Buenos Aires
CABA, 1182, Argentina
-
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, 15090-000, Brazil
-
General Hospital of Ningxia Medical University
Yinchuan, 750004, China
-
Glenfield Hospital
Leicester, LE3 9QP, United Kingdom
-
HOP Avicenne
Bobigny, 93000, France
-
HOP Bichat
Paris, 75018, France
-
HOP CHU Caen
Caen, 14033, France
-
HOP CHU de Grenoble
La Tronche, 38700, France
-
HOP Nord
Marseille, 13015, France
-
HOP Pontchaillou
Rennes, 35033, France
-
HOP d'Angers
Angers, 49933, France
-
HYKS Keuhkosairauksien tutkimusyksikkö
Helsinki, 000290, Finland
-
Hamamatsu University Hospital
Shizuoka, Hamamatsu, 431-3192, Japan
-
Heartlands Hospital
Birmingham, B9 5SS, United Kingdom
-
Henan Provincial People's Hospital
Zhengzhou, 450003, China
-
Henderson Clinical Trials
Henderson, Nevada, 89052, United States
-
Hiroshima Prefectural Hospital
Hiroshima, Hiroshima, 734-8530, Japan
-
Hiroshima University Hospital
Hiroshima, Hiroshima, 734-8551, Japan
-
Hopital Louis Pradel
Bron, 69677, France
-
Hopital Pasteur
Nice, 06000, France
-
Hospital Aleman
CABA, 1118, Argentina
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Elisabethinen Linz
Linz, 4020, Austria
-
Hospital General de Granollers
Granollers, 08402, Spain
-
Hospital Germans Trias i Pujol
Badalona, 08916, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitari de Bellvitge
Hospitalet Llobregat, 08907, Spain
-
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, 08907, Spain
-
Hospital Universitario Dr Jose Eleuterio Gonzalez
Monterrey, 64460, Mexico
-
Hospital Universitario Ramon Y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Reina Sofía
Córdoba, 14004, Spain
-
Hospital de Galdakao
Galdakao, 48960, Spain
-
Hospital of the University of Occupational and Environmental Health
Fukuoka, Kitakyushu, 807-8556, Japan
-
IMIP Pernambuco
Recife, 50070902, Brazil
-
INCOR e Hospital das Clínicas da Universidade de São Paulo
São Paulo, 05403-000, Brazil
-
INS Coeur Poumon
Lille, 59037, France
-
INSARES
Mendoza, M5500CCG, Argentina
-
Indiana University Health Enterprise Clinical Research Operation
Indianapolis, Indiana, 46202, United States
-
Inje University Busan Paik Hospital
Busan, 47392, South Korea
-
Inje University Haeundae Paik Hospital
Busan, 48108, South Korea
-
Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ)
Québec, G1V 4G5, Canada
-
Instituto Ave Pulmo - Fundacion Enfisema
Mar del Plata, 7600, Argentina
-
Instituto de Medicina Respiratoria (IMeR)
Alberdi Sur, X5003DCE, Argentina
-
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, 90050-170, Brazil
-
Johannes Kepler University Linz
Linz, 4020, Austria
-
Juntendo University Hospital
Tokyo, Bunkyo-ku, 113-8431, Japan
-
Kagawa University Hospital
Kagawa, Kita-gun, 761-0793, Japan
-
Kanagawa Cardiovascular and Respiratory Center
Kanagawa, Yokohama, 236-0051, Japan
-
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 83301, Taiwan
-
Kaohsiung Veterans General Hospital
Kaohsiung City, 81362, Taiwan
-
Keio University Hospital
Tokyo, Shinjuku-ku, 160-8582, Japan
-
Kelowna Respirology & Allergy Research
Kelowna, British Columbia, V1Y 3H5, Canada
-
Kindai University Hospital
Osaka, Sakai, 590-0197, Japan
-
Klinikum Region Hannover GmbH
Hanover, 30459, Germany
-
Klinikum der Universität München AÖR
München, 81377, Germany
-
Kyung Hee University Hospital
Seoul, 02447, South Korea
-
Lakeland Regional Medical Center - Lakeland
Lakeland, Florida, 33805, United States
-
Lowcountry Lung and Critical Care
Charleston, South Carolina, 29406, United States
-
Lungenfachklinik Immenhausen
Immenhausen, 34376, Germany
-
Mayo Clinic, Rochester
Rochester, Minnesota, 55905, United States
-
Medical University of Graz
Graz, 8036, Austria
-
Medizinische Hochschule Hannover
Hanover, 30625, Germany
-
Metroplex Pulmonary & Sleep Center
McKinney, Texas, 75069, United States
-
Nanjing Drum Tower Hospital
Nanjing, 210008, China
-
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji
Warsaw, 02-637, Poland
-
National Center for Global Health and Medicine
Tokyo, Shinjuku-ku, 162-8655, Japan
-
National Hospital Organization Kinki-Chuo Chest Medical Center
Osaka, Sakai, 591-8555, Japan
-
National Hospital Organization Kyushu Medical Center
Fukuoka, Fukuoka, 810-8563, Japan
-
National Institute Of Tuberculosis And Lung Diseases
Warsaw, 01-138, Poland
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Newport Native MD, Inc
Newport Beach, California, 92663, United States
-
Ospedale Classificato San Giuseppe
Milan, 20123, Italy
-
Ospedale Colonnello D Avanzo
Foggia, 71100, Italy
-
Ospedale G.B. Morgagni
Forlì, 47121, Italy
-
Oulun yliopistollinen keskussairaala
Oulu, 90220, Finland
-
People's Hospital of Sichuan Province
Chengdu, 610072, China
-
Pol. Universitario Tor Vergata
Roma, 00133, Italy
-
Przychodnia Alergologiczno-Pulmonologiczna Alergopneuma Sp. z o.o.
Świdnik, 21-040, Poland
-
Robert Bosch Gesellschaft für medizinische Forschung mbH
Stuttgart, 70376, Germany
-
Royal Brompton Hospital
London, SW3 6HP, United Kingdom
-
Royal Devon and Exeter Hospital, Wonford
Exeter, EX2 5DW, United Kingdom
-
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
Essen, 45239, Germany
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Sapporo Medical University Hospital
Hokkaido, Sapporo, 060-8543, Japan
-
Second Affiliated Hospital of medical college of Xi'an JiaoTong University
Xi'an, 710004, China
-
Seoul National University Bundang Hospital
Seongnam, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Shanghai Chest Hospital
Shanghai, 200030, China
-
Shanghai Pulmonary Hospital
Shanghai, 200433, China
-
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Hangzhou, 310016, China
-
Soon Chun Hyang University Hospital Bucheon
Bucheon-si, Gyeonggi-do, 14584, South Korea
-
Southeastern Research Center-Winston-Salem-61365
Winston-Salem, North Carolina, 27103, United States
-
St George's Hospital
London, SW17 0RE, United Kingdom
-
St James's University Hospital
Leeds, LS9 7TF, United Kingdom
-
St. Antonius Ziekenhuis
Nieuwegein, 3435 CM, Netherlands
-
St. Paul's Hospital (Vancouver)
Vancouver, British Columbia, V6Z 1Y6, Canada
-
Synergy Respiratory Care
Sherwood Park, Alberta, T8H 0N2, Canada
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
Taipei Veterans General Hospital
Taipei, 112, Taiwan
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
-
The First Affiliated Hospital of Soochow University
Suzhou, 215006, China
-
The Second Xiangya Hospital Of Central South University
Changsha, 410011, China
-
Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
Heidelberg, 69126, Germany
-
Tianjin Medical University General Hospital
Tianjin, 300052, China
-
Tokushima University Hospital
Tokushima, Tokushima, 770-8503, Japan
-
Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T
Wuhan, 430030, China
-
Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
-
Tosei General Hospital
Aichi, Seto, 489-8642, Japan
-
Turku University Hospital / TYKS
Turku, 20521, Finland
-
UT Health San Antonio
San Antonio, Texas, 78229, United States
-
UZ Leuven
Leuven, 3000, Belgium
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430022, China
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Southern California
Los Angeles, California, 90033, United States
-
University of Utah Health Sciences Center
Salt Lake City, Utah, 84108, United States
-
Universitätsklinikum Bonn AöR
Bonn, 53127, Germany
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-214, Poland
-
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
Poznan, 60-569, Poland
-
Vivantes Netzwerk für Gesundheit GmbH
Berlin, 12351, Germany
-
Weill Cornell Medicine-New York-60569
New York, New York, 10021, United States
-
West China Hospital, Sichuan University
Chengdu, 610041, China
-
Wiener Gesundheitsverbund
Vienna, 1140, Austria
-
Wiener Gesundheitsverbund
Vienna, 1210, Austria
-
Wuxi People's Hospital
Wuxi, 214043, China
-
Wythenshawe Hospital
Manchester, M23 9LT, United Kingdom
-
Yale University School of Medicine
New Haven, Connecticut, 06520, United States
-
Zhejiang Hospital
Hangzhou, 310013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sharper CT scans may solve a lung disease diagnostic puzzle
- Can a JAK inhibitor halt rapid lung decline?
- Could a vibrating platform help people with stiff lungs breathe easier?
- Frailty and muscle loss may predict outcomes in lung scarring patients
- Massive study tracks lung disease progression in 4,000 patients
- Massive 10-Year study aims to unlock secrets of rare lung disease